Compare BCTX & PRPO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BCTX | PRPO |
|---|---|---|
| Founded | 2014 | N/A |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Laboratory Analytical Instruments |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 28.8M | 32.4M |
| IPO Year | N/A | N/A |
| Metric | BCTX | PRPO |
|---|---|---|
| Price | $4.04 | $23.39 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $40.00 | N/A |
| AVG Volume (30 Days) | ★ 429.3K | 14.2K |
| Earning Date | 03-11-2026 | 03-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $22,800,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $380.95 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 30.95 |
| 52 Week Low | $4.01 | $3.90 |
| 52 Week High | $98.20 | $28.50 |
| Indicator | BCTX | PRPO |
|---|---|---|
| Relative Strength Index (RSI) | 37.31 | 52.07 |
| Support Level | $4.01 | $19.52 |
| Resistance Level | $4.42 | $25.00 |
| Average True Range (ATR) | 0.28 | 1.67 |
| MACD | 0.13 | -0.10 |
| Stochastic Oscillator | 5.23 | 51.88 |
BriaCell Therapeutics Corp is a clinical-stage biotechnology company focused on developing immunotherapies for cancer treatment, particularly breast cancer. The company's targeted immunotherapy program, Bria-IMT, is a targeted cell-based immunotherapy in end-stage clinical trials aiming to improve outcomes for patients with breast cancer. BriaCell also develops Bria-OTS, personalized off-the-shelf immunotherapies for breast and prostate cancer. BriaCell is involved in clinical collaborations to explore combination therapies for enhanced cancer treatment options.
Precipio Inc is a healthcare solutions company focused on cancer diagnostics. It focuses on addressing the problem of cancer misdiagnoses by developing solutions to mitigate the root causes of this problem in the form of diagnostic products, reagents, and services. The company operates Clinical Laboratory Improvement Amendments laboratories in both the New Haven, Connecticut and Omaha, Nebraska locations providing essential blood cancer diagnostics to office-based oncologists in many states nationwide. It provides new technologies to the oncology diagnostic laboratory market in the form of HemeScreen and IV-Cell product offerings. The company generates the majority of its revenue from third-party payers.